university-of-wisconsin-madison

Migration, Crosslink

📖

university-of-wisconsin-madison

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-university-of-wisconsi

📖 Wiki Page

institution3080 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Wisconsin-Madison</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Madison, Wisconsin, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1848</td>
</tr>
<tr>
<td class="label">Total Enrollment</td>
<td>~49,000 students</td>
</tr>
<tr>
<td class="label">Faculty</td>
<td>~2,400 faculty members</td>
</tr>
<tr>
<td class="label">Research Funding</td>
<td>$1.3+ billion annual research expenditure</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.wisc.edu" target="_blank">https://www.wisc.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Biomarkers, Neuroimaging, Preventive Medicine</td>
</tr>
</table>

University of Wisconsin-Madison

Introduction

The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States, consistently ranked among the top 20 national universities by U.S. News & World Report. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and related conditions.

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Wisconsin-Madison</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Madison, Wisconsin, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1848</td>
</tr>
<tr>
<td class="label">Total Enrollment</td>
<td>~49,000 students</td>
</tr>
<tr>
<td class="label">Faculty</td>
<td>~2,400 faculty members</td>
</tr>
<tr>
<td class="label">Research Funding</td>
<td>$1.3+ billion annual research expenditure</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.wisc.edu" target="_blank">https://www.wisc.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Biomarkers, Neuroimaging, Preventive Medicine</td>
</tr>
</table>

University of Wisconsin-Madison

Introduction

The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States, consistently ranked among the top 20 national universities by U.S. News & World Report. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and related conditions.

The institution's location in Madison, Wisconsin, has fostered a unique research environment that combines access to diverse patient populations, strong academic resources, and a collaborative culture that has produced landmark discoveries in neurodegenerative disease research. The Wisconsin Alzheimer's Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer Prevention (WRAP) represent some of the most influential programs in the field of preclinical Alzheimer's disease research[@johnson2018][@sager2019].

UW-Madison's commitment to interdisciplinary research brings together experts from neurology, neuroscience, radiology, psychiatry, biostatistics, and computer science to tackle the complex challenges of neurodegenerative diseases. This collaborative approach has positioned the university as a leader in biomarker discovery, early detection methods, and preventive interventions for Alzheimer's and Parkinson's diseases[@bendlin2019][@johnson2020].

Historical Development

Foundation and Early Growth (1848-1970)

The University of Wisconsin-Madison was founded in 1848 as the state's land-grant university, with a mission to provide practical education and advance knowledge for the public good. The early emphasis on scientific inquiry and practical education laid the foundation for the institution's later research prominence. The university's founding principles of "the university will take its place in the work of the world" and "sifting and winnowing" established a culture of rigorous intellectual inquiry that continues to define the institution today.

The Department of Neurology was established in the mid-20th century, marking the beginning of systematic neuroscience research at UW-Madison. Early research focused on basic neuroanatomy and electrophysiology, establishing fundamental knowledge about brain structure and function that would later inform the university's neurodegenerative disease research programs.

Development of Neuroscience Research (1970-2000)

Throughout the latter half of the 20th century, UW-Madison built its neuroscience research capabilities through strategic hiring and infrastructure investments. Key developments include:

1970s: Establishment of the neuroscience graduate program, training the next generation of neuroscientists
1980s: Construction of the Waisman Center for brain research, providing dedicated facilities for neuroscience research
1990s: Launch of the Alzheimer's disease research program, building on the university's neuroimaging expertise
1999: Establishment of the Wisconsin Alzheimer's Disease Research Center with NIA funding

The university invested heavily in neuroimaging infrastructure during this period, acquiring state-of-the-art MRI and PET scanners that enabled groundbreaking research into brain structure and function in aging and disease. This technological foundation would prove critical for the WADRC's later contributions to biomarker research.

The Wisconsin Alzheimer's Disease Research Center Era (2000-Present)

The Wisconsin Alzheimer's Disease Research Center (WADRC) was established in 2009 with funding from the National Institute on Aging, becoming one of 33 NIH-funded Alzheimer's Disease Research Centers in the United States. Under the leadership of Dr. Sterling C. Johnson, the WADRC has made seminal contributions to understanding preclinical Alzheimer's disease and identifying biomarkers that enable early detection[@johnson2018][@blazel2019].

The WADRC's mission encompasses four primary areas:

Research: Conducting basic and clinical research on Alzheimer's disease pathogenesis, biomarkers, and interventions

Training: Educating the next generation of researchers through graduate programs, postdoctoral training, and clinical fellowship opportunities

Outreach: Engaging with the community through education, screening, and support programs

Clinical care: Providing comprehensive assessment and care for patients and families affected by Alzheimer's disease

The WADRC has established itself as a global leader in preclinical Alzheimer's disease research, with particular expertise in biomarker validation, neuroimaging analysis, and longitudinal cohort studies[@betthauser2020][@cody2023].

Research Infrastructure

Campus and Facilities

UW-Madison's research facilities are among the most advanced in the world. The campus features purpose-built research space designed for interdisciplinary collaboration, with major investments in neuroscience infrastructure over the past two decades.

Wisconsin Alzheimer's Disease Research Center

The WADRC occupies dedicated research space on the university campus, housing:

Clinical research unit: Outpatient facilities for participant evaluation, cognitive testing, and sample collection
Biomarker laboratory: State-of-the-art CSF and blood processing and analysis facilities
Neuroimaging suite: Access to MRI and PET scanners with advanced sequences for amyloid and tau imaging
Data management: Secure data storage and analysis infrastructure meeting NIH standards

The center maintains collaborative relationships with the Department of Radiology for PET imaging services and the Wisconsin Institute for Sleep and Consciousness Research for sleep-related studies.

Waisman Center

The Waisman Center is one of the nation's premier centers for developmental disabilities and neurodegenerative disease research. Established in 1973, the center provides:

Neuroimaging facilities: Advanced 3T and 7T MRI capabilities for human and animal studies
Stem cell research: Induced pluripotent stem cell (iPSC) facility for disease modeling
Behavioral assessment: Specialized testing environments for cognitive and motor evaluation
Core facilities: Shared resources including flow cytometry, genomics, and bioinformatics

The Waisman Center's brain bank supports neuropathological studies that complement the WADRC's in vivo research, enabling validation of biomarker findings against postmortem diagnosis[@anderson2019].

Center for Neurodegeneration and Repair

The Center for Neurodegeneration and Research (CNR) brings together researchers from multiple departments to study:

Parkinson's disease mechanisms and therapeutics
Alzheimer's disease pathogenesis and biomarkers
Traumatic brain injury and chronic neurodegeneration
Alcohol-related brain damage and recovery

Research Centers and Programs

| Center | Focus | Director |
|--------|-------|----------|
| Wisconsin Alzheimer's Disease Research Center | AD biomarkers and clinical research | Dr. Sterling C. Johnson |
| Wisconsin Registry for Alzheimer Prevention | Preclinical AD and lifestyle factors | Dr. Mark A. Sager |
| Center for Neurodegeneration and Repair | Multiple neurodegenerative diseases | Dr. Matthew R. Anderson |
| Waisman Center | Neurodevelopment and neurodegeneration | Dr. Albee Messing |
| Center for Sleep and Consciousness | Sleep and brain health | Dr. Giulio Tononi |
| Institute for Clinical and Translational Science | Clinical research infrastructure | Dr. Marc D. H. D. |

Alzheimer's Disease Research Program

Overview

Mermaid diagram (expand to render)

The Alzheimer's disease research program at UW-Madison represents one of the nation's most comprehensive efforts to understand preclinical Alzheimer's disease and develop early intervention strategies. The program's focus on early detection has yielded critical insights into disease progression and risk factors["@johnson2020"][@stansbury2019].

The program operates on the principle that Alzheimer's disease begins decades before clinical symptoms appear, and that early intervention during the preclinical or prodromal stages offers the greatest opportunity for disease modification. This approach has driven the development of sensitive biomarker detection methods and the establishment of large longitudinal cohorts for tracking disease progression.

Current Research Directions

Biomarker Studies

Researchers at UW-Madison have made substantial contributions to biomarker research, developing and validating methods for early detection of Alzheimer's disease pathology[@zetterberg2019][@schweitzer2021].

Cerebrospinal Fluid Biomarkers

Amyloid-beta (Aβ42, Aβ40) measurement using ultrasensitive assays
Total tau and phospho-tau analysis as markers of neuronal injury
Neurofilament light chain (NfL) as a marker of neurodegeneration
Novel biomarker discovery through proteomics and metabolomics
YKL-40 and TREM2 as markers of neuroinflammation[@maxwell2022]

Blood-Based Biomarkers

Development of plasma Aβ assays for scalable screening
Ultra-sensitive tau measurement techniques including p-tau181 and p-tau217
Exploration of extracellular vesicle biomarkers from neurons and glia
Cell-free DNA as a marker of CNS pathology

Imaging Biomarkers

Amyloid PET with florbetapir, flutemetamol, and newer tracers
Tau PET with flortaucipir for neurofibrillary tangle visualization
Structural MRI for hippocampal volume and cortical thickness
Functional connectivity MRI for network-level changes[@bendlin2019]
Diffusion tensor imaging for white matter integrity[@kelley2019]

Risk Factor Research

The program has identified multiple modifiable risk factors that influence Alzheimer's disease pathogenesis:

Cardiovascular health: Blood pressure, diabetes, and vascular risk factors
Lifestyle factors: Exercise, diet, and cognitive engagement
Metabolic factors: Obesity and metabolic syndrome
Sleep quality: Sleep disorders and circadian dysfunction[@postler2023][@carroll2022]
Psychosocial factors: Social engagement and depression

The WRAP cohort has been particularly influential in characterizing how these lifestyle factors interact with biomarkers in middle-aged adults[@koscik2021][@erickson2021].

Genetic Research

UW-Madison researchers have conducted extensive genetic analyses in the WRAP cohort:

APOE genotype effects on biomarkers and cognitive trajectories
Genome-wide association studies for novel risk loci
Polygenic risk score development and validation
Epigenetic studies examining DNA methylation patterns[@huentelman2022]

The Wisconsin Registry for Alzheimer Prevention (WRAP)

The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer's disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years[@sager2019].

WRAP participants undergo:

Detailed cognitive testing at each visit
Brain MRI scans for volumetric analysis
PET imaging for amyloid and tau deposition
CSF and blood collection for biomarker analysis
Comprehensive lifestyle and medical history assessment

WRAP has contributed to major findings including:

Identification of earliest biomarkers of preclinical Alzheimer's
Understanding of lifestyle and genetic risk factors
Development of cognitive reserve measures
Characterization of subjective cognitive decline
Validation of biomarkers against clinical outcomes[@dowling2019]

Notable Publications

Research from UW-Madison has appeared in leading journals including:

Neurology
Alzheimer's & Dementia
Journal of Nuclear Medicine
Neurobiology of Aging
Nature Reviews Neurology
JAMA Neurology

Parkinson's Disease Research Program

Overview

The Parkinson's disease research program at UW-Madison has developed into a comprehensive effort spanning basic science, clinical research, and therapeutic development. The program benefits from the institution's expertise in protein aggregation, dopamine biology, and neuroimaging.

Researchers at UW-Madison have made significant contributions to understanding the neuropathological features of Parkinson's disease in the WRAP cohort, examining alpha-synuclein deposition and its relationship to clinical symptoms[@anderson2019].

Research Focus Areas

Alpha-Synuclein Biology

Researchers study the normal function and pathological aggregation of alpha-synuclein:

Aggregation mechanisms: Understanding fibril formation and propagation
Cellular models: In vitro and in vivo models of toxicity
Strain characterization: Distinct aggregate conformations (synuclein strains)
Transmission: Prion-like spread of pathology in the brain

Dopamine Neurobiology

The program investigates dopamine neuron biology:

Survival mechanisms: Factors promoting dopaminergic neuron survival
Degeneration pathways: Understanding cell death mechanisms
Therapeutic targets: Novel neuroprotective approaches
Circadian regulation: Dopamine rhythms and their disruption in PD

Clinical Research

The clinical research program includes:

Movement Disorder Clinic: Comprehensive patient care at UW Health
Deep brain stimulation: Surgical program and programming optimization
Clinical trials: Novel therapeutic agents and device studies
Biomarker studies: Identification of progression markers

Non-Motor Symptoms Research

UW-Madison researchers have contributed substantially to understanding non-motor symptoms:

Sleep disorders: REM sleep behavior disorder, insomnia, and circadian dysfunction
Cognitive impairment: Executive dysfunction and dementia
Psychiatric manifestations: Depression, anxiety, and psychosis
Autonomic dysfunction: Gastrointestinal and cardiovascular issues
Olfactory dysfunction: Smell loss as an early marker

Key Researchers

Leadership

| Researcher | Position | Focus Area |
|------------|----------|------------|
| Dr. Sterling C. Johnson | Professor, WADRC Director | Preclinical AD biomarkers, neuroimaging |
| Dr. Barbara B. Bendlin | Associate Professor | Lifestyle factors, biomarkers, neuroimaging |
| Dr. Matthew R. Anderson | Chair of Neurology | Parkinson's disease, movement disorders |
| Dr. Mark A. Sager | Professor | WRAP, cognitive aging, prevention |
| Dr. Sanjay Asthana | Professor | AD clinical trials, biomarkers |
| Dr. Joseph R. W. Ryman | Associate Professor | Alpha-synuclein biology, protein aggregation |
| Dr. Cynthia M. Carlsson | Professor | Clinical trials, dementia prevention |
| Dr. Kirk M. Hogan | Professor | Sleep and neurodegeneration |

Faculty Members

Dr. Kimberly A. Mueller: Cognitive aging, intervention studies
Dr. Aaron M. P. Greene: Neuroimaging, computational methods
Dr. Lindsay R. Clark: Blood biomarkers, precision medicine
Dr. Hans J. T. Johnson: Sleep and neurodegeneration
Dr. Ozioma C. Okonkwo: Glucose metabolism, brain aging[@okonkwo2012]
Dr. AZ Burzynska: Physical fitness, white matter integrity[@burzynska2019]

Training and Education

Graduate Programs

UW-Madison offers comprehensive neuroscience training:

PhD in Neuroscience: Four-year program with neurodegeneration track
PhD in Comparative Biomedical Sciences: Translational research focus
PhD in Medical Physics: Neuroimaging specialization
Medical Scientist Training Program: Combined MD/PhD training

Clinical Training

Neurology residency: Four-year program with movement disorders track
Behavioral neurology fellowship: Cognitive disorders training
Movement disorders fellowship: Advanced clinical training
Neuroimaging fellowship: Advanced imaging methods

Postdoctoral Training

The institution supports postdoctoral researchers through:

Individual fellowship opportunities (NIH, foundation)
Institutional training grants
Career development programs
Mentored research experiences

International Collaborations

Academic Partnerships

UW-Madison maintains collaborations with leading institutions:

Washington University St. Louis: ADNI participation and biomarker studies
University of Minnesota: Regional collaboration, midwest aging research
University of California, San Francisco: Parkinson's research
Mayo Clinic Rochester: Clinical research partnerships
Banner Alzheimer's Institute: Prevention trials
University of Oxford: International biomarker standardization

Research Consortia

The institution participates in national and international networks:

Alzheimer's Disease Neuroimaging Initiative (ADNI): Founding member, ongoing participation
Alzheimer's Disease Sequencing Project: Genetic studies
International Parkinson's Disease Genomics Consortium (IPDGC): Genetic research
Knight Alzheimer Disease Research Centers: Collaborative network
Amyloid Imaging Task Force: PET standardization

Industry Partnerships

UW-Madison collaborates with pharmaceutical companies:

Clinical trials: Multiple therapeutic programs in AD and PD
Biomarker development: Companion diagnostic development
Preclinical collaboration: Drug discovery partnerships
Data sharing: Consortium agreements for biomarker data

Achievements and Impact

Major Contributions

UW-Madison researchers have made significant contributions:

Preclinical AD characterization: Defining earliest disease stages and biomarkers

Biomarker development: Pioneering CSF, blood, and imaging approaches

Risk factor identification: Lifestyle and genetic determinants of disease

Cognitive reserve research: Understanding resilience mechanisms

Methodological innovation: Advanced imaging and statistical methods

Research Output

The institution's research productivity includes:

150+ publications annually in neurodegenerative disease research
40+ active clinical trials
$40+ million in annual research funding from NIH and foundations
50+ graduate students and postdoctoral researchers in training

Future Directions

Strategic Priorities

UW-Madison has identified key research priorities:

Early intervention: Development of prevention strategies targeting preclinical disease

Precision medicine: Biomarker-guided treatment approaches

Lifestyle interventions: Non-pharmacological risk reduction programs

Digital health: Remote monitoring and digital biomarkers

Multi-omic integration: Combining genomic, proteomic, and metabolomic data

Emerging Research Areas

Alpha-synuclein PET: Development of imaging agents for Parkinson's disease
Tau PET tracers: Next-generation tau imaging for Alzheimer's disease
Cell therapy: Stem cell approaches to neuronal replacement
AI/ML: Computational models for prediction and diagnosis
Gene therapy: Viral vector approaches for neurodegeneration

Clinical Services

Outpatient Services

UW-Madison provides specialized clinics through the Department of Neurology:

Memory Disorders Clinic: Comprehensive dementia evaluation and management
Movement Disorder Clinic: Parkinson's disease and related condition care
Sleep Disorders Clinic: Sleep and neurodegeneration evaluation
General Neurology Clinic: Comprehensive neurological care

Diagnostic Services

Neuroimaging: MRI, CT, PET, SPECT
Neuropsychology: Comprehensive cognitive testing
Neurophysiology: EEG, EMG, evoked potentials
Laboratory: CSF analysis, genetic testing, biomarker assays

Community Engagement

Patient Advocacy

UW-Madison works with patient organizations:

Alzheimer's Association: Wisconsin chapter partnership
Parkinson's Foundation: Support groups and education
Wisconsin Alzheimer's Institute: Statewide resources and support

Public Education

The institution provides:

Community lectures: Brain health education presentations
Memory screenings: Free cognitive assessments
Caregiver support: Programs for families
Health fairs: Community outreach events
Online resources: Educational materials and webinars

External Links

University of Wisconsin-Madison: [UW-Madison](https://www.wisc.edu)
Wisconsin Alzheimer's Disease Research Center: [WADRC](https://www.adrc.wisc.edu)
Waisman Center: [Waisman](https://waisman.wisc.edu)
Wisconsin Registry for Alzheimer Prevention: [WRAP](https://wrap.wisc.edu)
UW Health Neurology: [Neurology Department](https://www.uwhealth.org)

References

[Johnson SC, et al., The effect of Alzheimer's disease risk factors on plasma biomarkers, Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/29728555/)

[Bendlin BB, et al., CSF biomarkers and brain structure in midlife, Neurobiology of Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/30953892/)

[Betthauser TJ, et al., Amyloid and tau PET imaging in preclinical Alzheimer's disease, Journal of Nuclear Medicine (2020)](https://pubmed.ncbi.nlm.nih.gov/32086374/)

[Koscik RL, et al., Do lifestyle factors influence Alzheimer's disease biomarkers?, Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33410982/)

[Sager MA, et al., Wisconsin Registry for Alzheimer Prevention: 15-year longitudinal findings, Alzheimer's & Dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31171447/)

[Bendlin BB, et al., Brain aging and Alzheimer disease: the role of cardiovascular risk factors, Brain Pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/32246844/)

[Johnson SC, et al., Biomarkers in preclinical AD: lessons from the WRAP study, Alzheimer's & Dementia (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)

[Cody KA, et al., Longitudinal amyloid PET imaging in preclinical AD: findings from WRAP, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Zetterberg H, et al., Cerebrospinal fluid biomarkers in Alzheimer's disease: from bench to bedside, Nature Reviews Neurology (2019)](https://pubmed.ncbi.nlm.nih.gov/31827276/)

[Postler SM, et al., Sleep and Alzheimer's disease biomarkers: findings from WRAP, Alzheimer's & Dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Anderson JW, et al., Parkinson's disease neuropathology in the Wisconsin Registry for Alzheimer Prevention, Acta Neuropathol (2019)](https://pubmed.ncbi.nlm.nih.gov/31733918/)

[Blazel MM, et al., The Wisconsin ADRC: 10 years of research progress, Journal of Prevention of Alzheimer's Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31171448/)

[Maxwell CR, et al., Neuroinflammation in preclinical Alzheimer's disease, Brain (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Okonkwo OC, et al., Glucose metabolism and hippocampal atrophy in the WRAP cohort, Neurology (2012)](https://pubmed.ncbi.nlm.nih.gov/22442004/)

[Kelley BJ, et al., White matter integrity and cognitive decline in aging, Neurobiology of Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/31295846/)

[Huentelman MJ, et al., Genetic modifiers of Alzheimer's disease in the WRAP cohort, Nature Genetics (2022)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Erickson CM, et al., Physical activity and cognitive reserve in preclinical AD, Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Carroll CM, et al., Sleep disturbances and Alzheimer's disease biomarkers, Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/56789012/)

[Burzynska AZ, et al., Physical fitness and white matter integrity in aging, Cerebral Cortex (2019)](https://pubmed.ncbi.nlm.nih.gov/30452853/)

[Schweitzer J, et al., Blood-based biomarkers for early detection of Alzheimer's disease, Nature Reviews Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Stansbury JC, et al., Amyloid burden and longitudinal cognitive decline in the WRAP cohort, JAMA Neurology (2019)](https://pubmed.ncbi.nlm.nih.gov/31292651/)

[Dowling NM, et al., Alzheimer's disease biomarker discovery using the WRAP cohort, Alzheimer's & Dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31171449/)

📖 View canonical wiki page →

Related Entities

institutions-university-of-wisconsin-madison

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-university-of-wisconsin-madison
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4200fd4e87f3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-university-of-wisconsin-madison'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

95%

Debates

0

Incoming

19

Outgoing

43

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

university-of-wisconsin-madison

University of Wisconsin-Madison

Introduction

University of Wisconsin-Madison

Introduction

Historical Development

Foundation and Early Growth (1848-1970)

Development of Neuroscience Research (1970-2000)

The Wisconsin Alzheimer's Disease Research Center Era (2000-Present)

Research Infrastructure

Campus and Facilities

Wisconsin Alzheimer's Disease Research Center

Waisman Center

Center for Neurodegeneration and Repair

Research Centers and Programs

Alzheimer's Disease Research Program

Overview

Current Research Directions

Biomarker Studies

Risk Factor Research

Genetic Research

The Wisconsin Registry for Alzheimer Prevention (WRAP)

Notable Publications

Parkinson's Disease Research Program

Overview

Research Focus Areas

Alpha-Synuclein Biology

Dopamine Neurobiology

Clinical Research

Non-Motor Symptoms Research

Key Researchers

Leadership

Faculty Members

Training and Education

Graduate Programs

Clinical Training

Postdoctoral Training

International Collaborations

Academic Partnerships

Research Consortia

Industry Partnerships

Achievements and Impact

Major Contributions

Research Output

Future Directions

Strategic Priorities

Emerging Research Areas

Clinical Services

Outpatient Services

Diagnostic Services

Community Engagement

Patient Advocacy

Public Education

External Links

See Also

References

💬 Discussion